| All patients (n = 1003) | 1 L chemotherapy (n = 698) | 1 L IO monotherapy (n = 179) | 1 L targeted therapy (n = 126) |
---|---|---|---|---|
Proportion of study population, % | 100 | 69.6 | 17.8 | 12.6 |
Median follow-up (range), months | 9.2 (0.0–42.7) | 7.9 (0.0–42.7) | 12.7 (0.1–37.3) | 16.3 (0.1–37.1) |
Median age at diagnosis (range), years | 68 (28–93) | 68 (28–88) | 67 (48–90) | 70 (32–93) |
Sex, n (%) | ||||
 Male | 541 (53.9) | 395 (56.6) | 94 (52.5) | 52 (41.3) |
 Female | 462 (46.1) | 303 (43.4) | 85 (47.5) | 74 (58.7) |
Tumor histology, n (%) | ||||
 Adenocarcinoma | 635 (63.3) | 387 (55.4) | 131 (73.2) | 117 (92.9) |
 Squamous cell carcinoma | 243 (24.2) | 202 (28.9) | 38 (21.2) | 3 (2.4) |
 Large cell carcinoma | 6 (0.6) | 4 (0.6) | 2 (1.1) | 0 |
 Not specified | 119 (11.9) | 105 (15.0) | 8 (4.5) | 6 (4.8) |
TNM stage at diagnosis, n (%) | ||||
 T | ||||
  T X-4 | 938 (93.5) | 647 (92.7) | 170 (95.0) | 121 (96.0) |
  N/A | 65 (6.5) | 51 (7.3) | 9 (5.0) | 5 (4.0) |
 N | ||||
  N X-3 | 939 (93.6) | 648 (92.8) | 170 (95.0) | 121 (96.0) |
  N/A | 64 (6.4) | 50 (7.2) | 9 (5.0) | 5 (4.0) |
 M | ||||
  M1a | 524 (52.2) | 351 (50.3) | 114 (63.7) | 59 (46.8) |
  M1a | 166 (16.6) | 120 (17.2) | 22 (12.3) | 24 (19.0) |
  M1b | 310 (30.9) | 224 (32.1) | 43 (24.0) | 43 (34.1) |
  M1c | 3 (0.3) | 3 (0.4) | 0 | 0 |
ECOG PS score at diagnosis, n (%) | ||||
 0–1 | 759 (75.7) | 513 (73.5) | 157 (87.7) | 89 (70.6) |
 2+ | 244 (24.3) | 185 (26.5) | 22 (12.3) | 37 (29.4) |
EGFR+ status, n (%)b | ||||
 Documented | 19 (1.9) | 1 (0.1) | 0 | 18 (14.3) |
 Assumed | 89 (8.9) | 0 | 0 | 89 (70.6) |
ALK+ status, n (%)b | ||||
 Documented | 2 (0.2) | 0 | 0 | 2 (1.6) |
 Assumed | 17 (1.7) | 0 | 0 | 17 (13.5) |
PD-L1+ status, n (%)b | ||||
 Documented | 10 (1.0) | 3 (0.4) | 7 (3.9) | 0 |
 Assumed | 172 (17.1) | 0 | 172 (96.1) | 0 |